Status:
SUSPENDED
Pharmacokinetic Study of Synera™ in Neonates and Infants
Lead Sponsor:
ZARS Pharma Inc.
Conditions:
Pain
Eligibility:
All Genders
Up to 4 years
Phase:
PHASE4
Brief Summary
This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.
Eligibility Criteria
Inclusion
- Subject must be an infant of 1 to 4 months of age and weigh at least 2.5 kg or a neonate of 0 to 4 weeks postnatal age with a gestation period of at least 37 weeks, and weigh at least 1.8 kg.
- Subject is scheduled to have a medically indicated minor superficial procedure for which topical local anesthesia would provide a benefit.
- Subject has or will have an indwelling vascular access catheter for blood sampling at the time of the procedure visit. The indwelling vascular access catheter placement must be necessary for medical reasons other than the purposes of this study.
- The additional blood draws for the purposes of this study do not pose more than a minor risk to the health and welfare of the subject.
Exclusion
- Subject has known allergies or sensitivities to any component of Synera.
- Subject has clinically significant laboratory abnormalities.
- Subject has known multiple allergies that could indicate hypersensitive skin.
- Subject has known active atopic dermatitis at or near the patch application site.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2013
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00747669
Start Date
September 1 2008
End Date
April 1 2013
Last Update
March 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010